SG acquires AstraZeneca's Evusheld

Evusheld is a long-acting antibody candidate for COVID-19 treatment.

The government of Singapore has signed a purchase agreement with AstraZeneca to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19.

The supply will arrive in Singapore by year-end.

"Evusheld provides healthcare professionals and patients in Singapore with a new option to fight the virus. Additionally, Evusheld will provide another prevention option for high-risk populations, alongside vaccines, including for people who are immunocompromised and unable to develop the needed degree of protective response following COVID-19 vaccination," AstraZeneca Singapore Country President Vinod Narayanan said.

A Phase III trial showed an 88% reduced risk of severe COVID-19 or death when patients with mild-to-moderate COVID-19 were treated within three days of symptom onset. AstraZeneca has this week received Emergency Use Authorization for Evusheld from the US Food and Drug Administration for the prevention of COVID-19 and has filed for regulatory approvals in other countries.

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The loss will not have any material impact on the company.
Around 66 hotels have submitted to offer their rooms for hotel isolation.
He has been acting as group CEO since September 2021.
Bidding for these projects may commence in the first half of 2022.
Cardholders can now seek treatment from units where they did not register.
The system will be implemented this year.
The new facility will provide care for Indonesians who get treatment overseas.
The system was the only one of its kind in the country.
Healthcare Asia will be back on 3 January 2022. 
The additional patents aim to address supply issues.
Evusheld is a long-acting antibody candidate for COVID-19 treatment.
Despite NCDs accounting for 41 million deaths annually, they are still healthcare's 'blind spot', expert says.
The gala was held in celebration of World AIDS Day 2021.
It won in the International Human-Machine Competition on Diabetes Management.
The new facility is the first of its kind in Singapore.